Eloxx Pharmaceuticals Inc (ELOX)
0.825
+0.02
(+2.80%)
USD |
OTCM |
Apr 23, 16:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 2.593M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -88.46% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | 12.78 |
Price to Book Value | -- |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | -- |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 99.89% |
Profile
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in the science of ribosome modulation, leveraging both its ZM chemistry technology platform and its library of novel aminoglycosides to develop novel oral small molecule Ribosome Modulating Agents (RMAs) and Eukaryotic Ribosome Selective Glycosides (ERSGs), for the treatment of rare and ultra-rare genetic diseases where patients have point nonsense genetic mutations that result in premature stop codons and less than full-length proteins. The ELX-02, the company'sĀ investigational drug product candidate, is a small molecule designed to restore the production of full-length functional proteins. |
URL | https://www.eloxxpharma.com |
Investor Relations URL | N/A |
HQ State/Province | Massachusetts |
Sector | Health Care |
Industry | Pharmaceuticals |
Equity Style | Small Cap/Value |
Next Earnings Release | May. 15, 2024 (est.) |
Last Earnings Release | Nov. 13, 2023 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in the science of ribosome modulation, leveraging both its ZM chemistry technology platform and its library of novel aminoglycosides to develop novel oral small molecule Ribosome Modulating Agents (RMAs) and Eukaryotic Ribosome Selective Glycosides (ERSGs), for the treatment of rare and ultra-rare genetic diseases where patients have point nonsense genetic mutations that result in premature stop codons and less than full-length proteins. The ELX-02, the company'sĀ investigational drug product candidate, is a small molecule designed to restore the production of full-length functional proteins. |
URL | https://www.eloxxpharma.com |
Investor Relations URL | N/A |
HQ State/Province | Massachusetts |
Sector | Health Care |
Industry | Pharmaceuticals |
Equity Style | Small Cap/Value |
Next Earnings Release | May. 15, 2024 (est.) |
Last Earnings Release | Nov. 13, 2023 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |